Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients.
This study aims to identify the effects of antipsychotics on plasma proteins, and on the proteins associated with schizophrenia. We applied proteomics technology to screen protein aberrations in Sprague-Dawley rats treated with antipsychotics and schizophrenic patients undergoing medication. ApoA-I was found significantly increased in the chlorpromazine-treated rats and decreased in the patients with treatment-resistant schizophrenia, which suggest that decreased levels of apoA-I might be associated with the pathology of schizophrenia and that chlorpromazine increases apoA-I levels as part of its therapeutic action.
La
Y J
YJ
Bio-X Center, Shanghai Jiao Tong University, Shanghai, PR China.
Wan
C L
CL
Zhu
H
H
Yang
Y F
YF
Chen
Y S
YS
Pan
Y X
YX
Feng
G Y
GY
He
L
L
D000328:Adult; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D016632:Apolipoprotein A-I / Q000097:blood*; D001054:Apolipoproteins A / Q000097:blood; D001057:Apolipoproteins E / Q000097:blood; D015415:Biomarkers / Q000032:analysis / Q000097:blood; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D001923:Brain Chemistry / Q000187:drug effects / Q000502:physiology*; D002746:Chlorpromazine / Q000494:pharmacology; D003024:Clozapine / Q000494:pharmacology; D015536:Down-Regulation / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008297:Male; D040901:Proteomics; D051381:Rats; D017207:Rats, Sprague-Dawley; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy* / Q000503:physiopathology
D014150:Antipsychotic Agents; D016632:Apolipoprotein A-I; D001054:Apolipoproteins A; D001057:Apolipoproteins E; D015415:Biomarkers; C022205:apolipoprotein A-IV; D003024:Clozapine; D002746:Chlorpromazine